Add BrightSurf on Google Email

New Reichman University study: Advances in cancer treatment and research: ChiTaRS 8.0 database of chimeric genes launched to facilitate the precise adaptation of treatments to specific cancer types

The ChiTaRS 8.0 database is the world's largest collection of chimeric genes found in humans with cancer and other chronic diseases. It enables the precise adaptation of treatments to specific cancer types, improving treatment success and minimizing side effects.

SourceReichman University·JournalNucleic Acids Research·TypeRandomized controlled/clinical trial·DateJan 1, 2025

Research by City of Hope and other scientists may help patients overcome resistance to chimeric antigen receptor (CAR) T cell therapy

City of Hope researchers and collaborators have developed a new method to facilitate encoding numerous features in T cells, allowing for the simultaneous targeting of multiple tumor escape mechanisms. The 'zip-sorting' system doubles genetic information capacity, enabling improved anti-tumor activity and longer-lived T cells.

SourceCity of Hope·JournalNature Biomedical Engineering·DateDec 23, 2024

What is metformin’s secret sauce?

A new Northwestern Medicine study reveals how metformin lowers glucose levels by targeting mitochondrial complex I in cells. The drug also improves COVID outcomes and reduces inflammation, suggesting that mitochondrial complex I inhibition may be a unifying mechanism behind its diverse effects.

SourceNorthwestern University·JournalScience Advances·DateDec 18, 2024

Generative AI against diseases: Insilico Medicine announced Pharma.AI-powered HPK1 inhibitor series in peer-reviewed publication trilogy, as potential immunotherapy options

The study uses generative AI to identify and optimize potent and selective HPK1 inhibitors for immunotherapy. The results show a relatively balanced candidate compound with adequate in vitro ADME, in vivo PK properties, good oral bioavailability, and robust in vivo efficacy in various cancer models.

Breakthrough in treatment approach showing promise in the fight against glioblastoma, the deadliest and most aggressive type of brain cancer

A phase 2 study conducted by Mayo Clinic found that 56% of participants were alive after 12 months, with a median overall survival of 13.1 months. The treatment, which combines short-course hypofractionated proton beam therapy with advanced imaging techniques, was more effective in patients over 65 with favorable tumor genetics.

SourceMayo Clinic·JournalThe Lancet Oncology·DateDec 16, 2024

Children’s Hospital of Philadelphia, Stanford Researchers reveal and refine new immunotherapy platform with increased potential to target cancer cells

Researchers at Children's Hospital of Philadelphia and Stanford University have developed a new immunotherapy platform called TRACeR-I, which can more accurately recognize a wide variety of surface proteins expressed by cancer cells. This improved recognition enables the body's own immune system to target cancer cells more effectively.

SourceChildren's Hospital of Philadelphia·JournalNature Biotechnology·TypeExperimental study·DateDec 13, 2024

SABCS: Improved survival for advanced breast cancer, using genomics to identify patients with high risk of recurrence, how race/ethnicity influence the risk of heart failure in early-stage breast cancer and more

Researchers at UCLA Health presented several breakthroughs at the San Antonio Breast Cancer Symposium, including improved survival rates for advanced breast cancer patients who receive trastuzumab deruxtecan (T-DXd), a novel ADC. Additionally, new genomic testing and circulating tumor DNA analysis may help identify high-risk patients a...

Network-based analyses uncover how neuroinflammation-causing microglia in Alzheimer’s disease form

Researchers have developed a network-based approach to understand how immune cells called microglia transform and drive harmful processes like neuroinflammation in Alzheimer's disease. The study identified three unique subtypes of harmful microglia that promote disease progression, with genetic signatures driving their behaviors.

SourceCleveland Clinic·JournalAlzheimer’s & Dementia·DateDec 6, 2024

Genetic data from ‘biobanks’ may help improve prediction of effectiveness, side effects of common medications, study finds

A new framework developed by UCLA researchers suggests that genetic data from large libraries of sequenced human genomes can improve the predictive power of genetics in determining how well a patient will respond to commonly prescribed medications and the severity of any side effects. The study, which analyzed data from over 342,000 pe...

Study reveals how deadly brain tumor evades treatment; identifies potential new treatment strategy

A new study from UCLA Health Jonsson Comprehensive Cancer Center introduces a combined genetic and functional profiling approach to predict how glioblastoma will respond to therapy. The approach helps identify new ways to target and treat the tumors more effectively, including using an experimental drug called ABBV-155.

Genetic variation enhances cancer drug sensitivity

A recent study from Uppsala University found that genetic variation in cancer cells can enhance the effects of an already approved cancer drug, talazoparib, against liver cancer cells lacking a functional CYP2D6 enzyme. This suggests a potential for more individually tailored and effective cancer therapies.

SourceUppsala University·JournalEBioMedicine·TypeExperimental study·DateNov 14, 2024

POSTECH team pioneers new cancer therapy strategy: targeting GLUT3 in regulatory T cells to supercharge anti-tumor immunity

Researchers at POSTECH have identified GLUT3 as essential for the suppressive function of regulatory T cells in tumor microenvironments, which can be targeted for cancer immunotherapy. The team's findings highlight the critical role of GLUT3 in regulating protein modifications that sustain immune suppression within tumors.

SourcePohang University of Science & Technology (POSTECH)·JournalCellular and Molecular Immunology·DateNov 12, 2024